Is Cytek Biosciences, Inc. technically bullish or bearish?
2025-11-04 11:34:33As of 31 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, while weekly and monthly MACD and Dow Theory show mildly bullish signals. However, the overall bearish sentiment is reinforced by the KST being bearish on a monthly basis and Bollinger Bands indicating a mildly bearish trend monthly. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -39.29% compared to the S&P 500's 16.30%....
Read MoreIs Cytek Biosciences, Inc. technically bullish or bearish?
2025-11-03 11:34:18As of 31 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a bearish trend, while the weekly KST is mildly bearish. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, this is offset by the overall bearish indicators. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -39.91% versus the S&P 500's 16.30%....
Read MoreIs Cytek Biosciences, Inc. technically bullish or bearish?
2025-11-02 11:18:46As of 31 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish overall, with daily moving averages indicating a bearish signal. Weekly indicators show a mixed picture with MACD and Dow Theory both mildly bullish, while KST is mildly bearish. The Bollinger Bands present a mildly bullish outlook on the weekly but shift to mildly bearish on the monthly. In terms of performance, the stock has underperformed significantly against the S&P 500, with a year-to-date return of -39.91% compared to the S&P's 16.30%, and a one-year return of -21.13% versus 19.89% for the index....
Read MoreIs Cytek Biosciences, Inc. technically bullish or bearish?
2025-10-28 11:43:57As of 24 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on both weekly and monthly time frames, while the RSI indicates bearish momentum on the weekly and no signal on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly, and moving averages are mildly bearish on the daily. KST is bullish weekly but bearish monthly, and Dow Theory reflects a mildly bullish stance on both time frames. OBV shows a bullish monthly trend but no trend weekly. There is no available multi-period return data to compare against the S&P 500....
Read MoreIs Cytek Biosciences, Inc. technically bullish or bearish?
2025-10-27 11:55:07As of 24 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The weekly MACD is mildly bullish, while the RSI is bearish, indicating some weakness in momentum. The Bollinger Bands suggest a bullish stance on the weekly but mildly bearish on the monthly. Moving averages on the daily are mildly bearish, contrasting with the weekly and monthly Dow Theory, which are both mildly bullish. Overall, the indicators present a conflicting picture, leading to a neutral stance. Multi-period return data is not available for comparison with the S&P 500....
Read MoreIs Cytek Biosciences, Inc. technically bullish or bearish?
2025-10-26 11:29:52As of 24 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows bearish momentum on the weekly and no signal on the monthly. Bollinger Bands indicate a bullish weekly trend but a mildly bearish monthly trend. Moving averages are mildly bearish on the daily, and the KST shows a bullish weekly but bearish monthly stance. Dow Theory is mildly bullish on both weekly and monthly time frames. The OBV is bullish on the monthly but shows no trend on the weekly. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 7.85% and 24.93%, respectively, compared to the S&P 500's 1.92% and 2.32%. However, year-to-date and one-year returns are significantly...
Read More
Cytek Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
2025-10-13 15:44:51Cytek Biosciences, Inc. has experienced notable stock fluctuations, closing at $3.94 with a 52-week range of $2.37 to $7.63. Technical indicators present mixed signals, reflecting volatility. The company's performance has lagged behind the S&P 500, with significant declines year-to-date and over the past year.
Read MoreIs Cytek Biosciences, Inc. technically bullish or bearish?
2025-09-20 19:59:00As of 29 August 2025, the technical trend for Cytek Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while the weekly MACD shows a mildly bullish signal. However, the monthly MACD and KST are bearish, contributing to the overall bearish sentiment. The stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -36.98% compared to the S&P 500's 12.22%....
Read MoreIs Cytek Biosciences, Inc. overvalued or undervalued?
2025-09-20 18:32:48As of 9 May 2023, the valuation grade for Cytek Biosciences, Inc. moved from attractive to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.15, an EV to Sales ratio of 0.96, and a troubling ROCE of -20.58%. In comparison to peers, Cytek's EV to EBITDA ratio of -11.49 is significantly worse than Paragon 28, Inc. at -52.8268 and SI-BONE, Inc. at -25.8938, both of which also carry a risky valuation grade. The stock has underperformed relative to the S&P 500, with a year-to-date return of -36.98% compared to the index's positive return of 12.22%. This underperformance reinforces the view that Cytek Biosciences, Inc. is currently overvalued in the market....
Read More





